Keywords: لنفوم کیناز Anaplastic; irAE; immune related adverse event; ECOG PS; European cooperative oncology group performance status; n.s.; not significant; EGFR; epidermal growth factor receptor; ALK; anaplastic lymphoma kinase; PD-L1; programmed death-ligand 1; TKI; tyrosine-kinase inh
مقالات ISI لنفوم کیناز Anaplastic (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: لنفوم کیناز Anaplastic; Anaplastic lymphoma kinase; Deep vein thrombosis; Non small cell lung cancer; Pulmonary embolism; Thromboembolism;
Keywords: لنفوم کیناز Anaplastic; PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: لنفوم کیناز Anaplastic; Histone methylation; Histone demethylation; Lung cancer; Histone methyltransferase; Histone demethylase; Inhibitors; ALK; anaplastic lymphoma kinase; DUSP3; dual-specificity phosphatase 3; Elk1; ETS-domain containing protein; EMT; epithelial-to-mesenchyma
Keywords: لنفوم کیناز Anaplastic; NSCLC; Non-Small Cell Lung Carcinoma; SCLC; Small Cell Lung Carcinoma; AC; Adenocarcinoma; LCT; Lung Carcinoid Tumor; LCC; Large Cell Carcinoma; CTC; Circulating Tumor Cells; UICC; The Union for International Cancer Control; CT; Computer-based Tomography;
Keywords: لنفوم کیناز Anaplastic; 5-FU; 5-fluorouracil; AF; atrial fibrillation; ALK; anaplastic lymphoma kinase; APD; action potential duration; APL; acute promyelocytic leukemia; BCR-ABL; breakpoint cluster region-Abelson; BTK; Bruton tyrosine kinase; CD20; cluster of differentiation 20
Keywords: لنفوم کیناز Anaplastic; ALK; Anaplastic Lymphoma Kinase; CI; Confidence interval; CT; Computerized Tomography; EGFR; Epidermal Growth Factor Receptor; ESMO; European Society of Medical Oncology; 18F-FDG; Fluorodeoxyglucose; IQR; Interquartile range; MATV; Metabolic Active Tumor
Keywords: لنفوم کیناز Anaplastic; Personalized medicine; Non-small cell lung cancer; Pharmacogenomics; Tyrosine kinase; Anaplastic lymphoma kinase; Inhibitor; Monoclonal antibody;
Keywords: لنفوم کیناز Anaplastic; NSCLC; non-small cell lung cancer; EGFR; epidermal growth factor receptor; OR; odds ratio; HR; hazards ratio; CI; confidence interval; ALK; anaplastic lymphoma kinase; OS; overall survival; NHIS; National Health Insurance Service; NHID; National Health In
Keywords: لنفوم کیناز Anaplastic; AE; adverse event; ALK; anaplastic lymphoma kinase; aNSCLC; advanced non-small cell lung cancer; DRG; diagnosis-related group; EGFR; epidermal growth factor receptor; GLM; generalized linear model; HMO; health maintenance organization; HR; hazard ratio; I
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; ATP; adenosine triphosphate; BCR-ABL; Breakpoint cluster region-Abelson; DMEM; Dulbecco Modified Eagle Medium; EGFR; epidermal growth factor receptor; FUCCI; Fluorescence Ubiquitination Cell Cycle Indicator; HER; human e
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; CAF; cancer-associated fibroblast; CSC; cancer stem cell; CRC; colorectal cancer; EMT; epithelial-to-mesenchymal transition; EGFR; epidermal growth factor receptor; HH; hedgehog; HGF; hepatocyte growth factor; IGF; insulin
Keywords: لنفوم کیناز Anaplastic; NSCLC; non-small-cell lung cancer; PDX; patient-derived xenograft model; ALK; anaplastic lymphoma kinase; YHIM; Yonsei Human In Mouse; MAF; mutant allele frequency; H&E; hematoxylin and eosin; Non-small-cell lung cancer; Patient-derived xenograft; Preclin
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; CB; cell block; EBUS-GS; endobronchial ultrasonography with guide sheath; EBUS-TBB; endobronchial ultrasonography-guided transbronchial lung biopsy; TBB; transbronchial lung biopsy; Aspiration method; Bronchoscopy; Cell bl
Keywords: لنفوم کیناز Anaplastic; Lung adenocarcinoma; Epidermal growth factor receptor gene mutation; Adrenocortical carcinoma; Menin; Multiple endocrine neoplasia type 1; Immunohistochemistry; ACC; adrenocortical carcinoma; ALK; anaplastic lymphoma kinase; CT; computed tomography; EGFR;
Keywords: لنفوم کیناز Anaplastic; ALK-positive lung cancer; Anaplastic lymphoma kinase; Lung cancer; Adenocarcinoma;
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; DCTN1; dynactin 1; EGFR; epidermal growth factor receptor; EML4; microtubule-associated protein-like 4; FISH; fluorescence in situ hybridization; GLCI; Guangdong Lung Cancer Institute; HELP; hydrophobic EMAP-like protein;
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; CTLs; cytotoxic T lymphocytes; DLBCL; diffuse large B-cell lymphoma; ECOG-PS; Eastern Cooperative Oncology Group Performance Status; mAb; monoclonal antibody; NSCLC; non-small cell lung cancer; non-SQC; non-squamous cell l
Keywords: لنفوم کیناز Anaplastic; EGFR; Epidermal growth factor receptor; TP53; Tumor protein p53; KRAS; Kirsten rat carcoma viral oncogene; ALK; Anaplastic lymphoma kinase; RTK; Protein receptor tyrosine kinase; TKI; Tyrosine kinase inhibitor; PI3K; Phosphatidylinositol 3-kinase; NSCLC;
Keywords: لنفوم کیناز Anaplastic; SNPs; single-nucleotide polymorphisms; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; ADC; lung adenocarcinoma; LCINS; lung cancer in never-smokers; ALK; anaplastic lymphoma kinase; GWAS; genome-wide association studies; HKU/HA
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; CNS; central nervous system; EGFR; epidermal growth factor receptor; FDA; food and drug administration; GCN; gene copy number; HGF; hepatocyte growth factor; IC50; half inhibitory concentration; IHC; immunohistochemistry;
Keywords: لنفوم کیناز Anaplastic; anaplastic lymphoma kinase; inflammatory pseudotumor; inflammatory myofibroblastic tumor; intraocular pseudotumor; lens-induced uveitis; phacoantigenic uveitis;
Keywords: لنفوم کیناز Anaplastic; Lung adenocarcinoma; Anaplastic lymphoma kinase; Crizotinib; Resistance; Small cell lung carcinoma;
Keywords: لنفوم کیناز Anaplastic; Anaplastic lymphoma kinase; Crizotinib; Cystic brain metastases; Non-small-cell lung cancer; Signet ring morphology;
Keywords: لنفوم کیناز Anaplastic; 2-AG; 2-arachidonoylglycerol; ALK; anaplastic lymphoma kinase; ATF-4; activating transcription factor 4; CB1; cannabinoid CB1 receptor; CB2; cannabinoid CB2 receptor; CBD; cannabidiol; CHOP; C/EBP homologous protein; EGFR; epidermal growth factor receptor
Keywords: لنفوم کیناز Anaplastic; Acquired cystic disease-associated RCC; ALK; anaplastic lymphoma kinase; atrophic kidney-like renal tumour; Birt–Hogg–Dubé syndrome-associated renal tumour; clear cell papillary RCC; HLRCC associated RCC; succinate dehydrogenase-deficient RCC; thyroid-lik
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; ALL; acute lymphoblastic leukemia; CLL; chronic lymphocytic leukemia; CML; chronic myelogenous leukemia; CNS; central nervous system; CRC; colorectal cancer; DTC; differentiated thyroid carcinoma; DUSP; dual specificity ph
Keywords: لنفوم کیناز Anaplastic; Targeted receptor TKIs; Acquired resistance to receptor TKIs; Overcoming drug resistance; Driver oncogenes; Gate keeper receptor mutations; Bypass signaling molecules; ABC; ATP-binding cassette; AKT/PKB; Protein kinase B; ALK; Anaplastic lymphoma kinase;
Keywords: لنفوم کیناز Anaplastic; Anaplastic lymphoma kinase; In situ hybridization; Immunohistochemistry; Crizotinib; Biopsy sample
Keywords: لنفوم کیناز Anaplastic; Anaplastic lymphoma kinase; Crizotinib; Creatinine; Glomerular filtration rate
Keywords: لنفوم کیناز Anaplastic; Lung cancer; Non-small-cell lung cancer; Never smokers; Epidermal growth factor receptor; EGFR; Anaplastic lymphoma kinase; ALK; KRAS; Tumor genotype; Failure; Bone specimen; Core biopsy; Molecular testing;
Keywords: لنفوم کیناز Anaplastic; EGFR; epidermal growth factor receptor (EGFR); ErbB; epidermal growth factor receptor family (ErbB); PI3K; phosphatidylinositol 3-kinase (PI3K); AKT; protein kinase B; mTOR; mammalian target of rapamycin; VEGF; vascular endothelial growth factor; ALK; ana
Keywords: لنفوم کیناز Anaplastic; Growth factors; Interaction; Proliferation; Migration; Protect and label; a.a.; amino acid; ALK; anaplastic lymphoma kinase; ASP; aspartic acid; CTGF; connective tissue growth factor; FGF-2; fibroblast growth factor-2; GLU; glutamic acid; HARP; heparin af
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; EGFR; epidermal growth factor receptor; FGFR; fibroblast growth factor receptor; FISH; fluorescence in situ hybridization; MET; mesenchymal epithelial transition; NGS; next-generation sequencing; SQCC; squamous cell carcin
Keywords: لنفوم کیناز Anaplastic; World Health Organization classification; Histopathology; Molecular pathology; Epidermal growth factor receptor; Anaplastic lymphoma kinase
Keywords: لنفوم کیناز Anaplastic; VEGF(R); vascular endothelial growth factor (receptor); EGF(R); epidermal growth factor (receptor); LGG; low-grade glioma; HGG; high-grade glioma; DIPG; diffuse intrinsic pontine glioma; PDGF(R); platelet derived growth factor (receptor); P(I)GF; placenta
Keywords: لنفوم کیناز Anaplastic; Lung cancer; Non-small-cell lung cancer; Never smokers; Epidermal growth factor receptor; EGFR; Anaplastic lymphoma kinase; ALK; KRAS;
Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; EMA; European Medicines Agency; EML4; echinoderm microtubule-associated protein-like 4; ESI; electro spray ionization; FDA; Food and Drug Administration; IS; internal standard; LC-MS/MS; liquid chromatography-tandem mass s
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Keywords: لنفوم کیناز Anaplastic; Proteolysis targeting chimera; Anaplastic lymphoma kinase; Degradation; Degrader; Von Hippel Lindau; Cereblon;
Identification of NMU as a potential gene conferring alectinib resistance in non-small cell lung cancer based on bioinformatics analyses
Keywords: لنفوم کیناز Anaplastic; NSCLC; non-small cell lung cancer; ALK; anaplastic lymphoma kinase; GEO; gene expression omnibus; DEGs; differentially expressed genes; DAVID; database for annotation, visualization and integrated discovery; GO; gene ontology; KEGG; kyoto encyclopedia of
Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; BSA; body surface area; Ccr; creatinine clearance; CI; confidence interval; CR; complete response; CTCAE; common terminology criteria for adverse events; DCR;
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Keywords: لنفوم کیناز Anaplastic; AE; adverse event; ALK; anaplastic lymphoma kinase; CR; complete response; DCR; disease control rate; ECOG PS; Eastern Cooperative Oncology Group Performance Status; EGFR; epidermal growth factor receptor; HR; hazard ratio; irAE; immune related adverse ev
Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506)
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; CI; confidence interval; CTONG; Chinese Thoracic Oncology Group; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; MERAF; Medical Record Abstraction Form; NSCLC; non-small cell lung cancer;
ALK is required for NLRP3 inflammasome activation in macrophages
Keywords: لنفوم کیناز Anaplastic; ALK; Macrophage; Inflammasome; NF-κB; Lipid peroxidation; PAMP; pathogen-associated molecular pattern molecule; DAMP; damage-associated molecular pattern molecule; NLRP3; NLR family pyrin domain containing; PYCARD; PYD and CARD doma0069n containing; ATP;
5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(2-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)phenyl)pyrimidine-2,4-diamine (WY-135), a novel ALK inhibitor, induces cell cycle arrest and apoptosis through inhibiting ALK and its downs
Keywords: لنفوم کیناز Anaplastic; WY-135; Anaplastic lymphoma kinase; Karpas299â¯cells; H2228â¯cells; Apoptosis;
Radiogenomics and IR
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; BAP1; BRCA1-associated protein 1; EGFR; epidermal growth factor receptor; HCC; hepatocellular carcinoma; HIF1a; hypoxia-inducible factor-1-alpha; KDM5C; lysine-specific demethylase 5C; KRAS; Kirsten rat sarcoma viral oncog
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
Keywords: لنفوم کیناز Anaplastic; ALK; anaplastic lymphoma kinase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; cMET; tyrosine-protein kinase Met/hepatocyte growth factor receptor; CT; computer tomography; ECOG; PS Eastern Cooperative Oncology Group performance status; EGFR; epide
Exosomes as a liquid biopsy for lung cancer
Keywords: لنفوم کیناز Anaplastic; Alix; ALG 2 interacting protein X; ALK; anaplastic lymphoma kinase; AREG; Amphiregulin; Atg2; autophagy related protein 2; AUC; area under the curve; BAL; bronchoalveolar lavage; circRNA; circular RNA; CSE; cigarette smoke extract; CTC; circulating tumor
Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy
Keywords: لنفوم کیناز Anaplastic; AE; adverse event; ALK; anaplastic lymphoma kinase; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CI; confidence interval; CR; complete response; ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; HR; hazar
Oncogenic Function of a KIF5B-MET Fusion Variant in Non-Small Cell Lung Cancer
Keywords: لنفوم کیناز Anaplastic; ADC; adenocarcinoma; ALK; anaplastic lymphoma kinase; CT; computed tomography; HGF; hepatocyte growth factor; IHC; immunohistochemical; KIF5B; kinesin family member 5b; MET; MET proto-oncogene, receptor tyrosine kinase; NSCLC; non-small cell lung cancer;